Nebraska's Medical Cannabis Rollout Stalls Amid Fees, Lawsuits

October 23, 2026

Photo by Derks24 via Pixabay.

Nebraska voters didn't just approve medical cannabis in November 2024 -- they approved it by margins that would make most ballot measures blush. Seventy-one percent backed legalizing possession of up to five ounces for qualifying patients, and sixty-seven percent voted to create a Medical Cannabis Commission to regulate the whole thing. Two separate measures, two landslide results, in a state that isn't exactly known for progressive drug policy. And yet two years later, not a single patient in Nebraska has been able to walk into a dispensary and legally buy a cannabis product.

The commission finally licensed its first cultivator in October 2025, a full year after the vote. But as of October 2026, there's still no licensed testing lab anywhere in the state, no licensed manufacturer, no licensed transporter, and no licensed dispensary. That's not a rounding error in a rollout -- that's the entire supply chain missing everything except the first link.

Meanwhile, a grower near Raymond has plants that are weeks from harvest with nowhere legal to send them once they're cut. The commission says its hands are tied until fee structures get formal sign-off. And just last month, the Nebraska Supreme Court finally put to rest the last serious legal threat to the program -- two lawsuits from a former state senator that, had they succeeded, could have unraveled the whole thing. The courtroom fight is over. The bureaucratic one is just getting started.

A Landslide Vote, Then a Slow Start

Photo by 12019 via Pixabay.

It's worth sitting with how decisive the 2024 vote actually was. Nebraska Initiative 437 legalized possession of up to five ounces of cannabis for patients with a qualifying condition and a doctor's recommendation, passing with roughly 71% support. Its companion, Initiative 438, created the Medical Cannabis Commission to license and regulate the supply chain, and it cleared with about 67%. These aren't narrow, contested results from a swing county -- they're the kind of numbers that cross party lines and geography in a state where Republicans hold every statewide office.

Despite that mandate, the commission itself didn't begin operating until June 2025 -- seven months after Nebraskans voted. That lag set the tone for everything that followed. And the program the commission was tasked with building is a tightly bounded one by design: just four cultivator licenses, four manufacturer licenses, and twelve dispensary licenses, one per judicial district statewide. Vertical integration is explicitly prohibited, so a company holding a cultivation license can't also hold a dispensary license -- a structural choice meant to prevent any single operator from controlling the chain from seed to sale.

The product list is narrower still. Smokable flower is banned under the program as written, along with vaping products and edibles. Patients approved for the program will be limited to things like tinctures, capsules, and other non-combustible, non-inhalable forms -- a far cry from what medical cannabis patients can access in states like Colorado or Michigan. It took until October 2025 for the first cultivation licenses to actually go out the door, nearly a year to the day after voters approved the measures that were supposed to make this happen.

Ready to Harvest, Nowhere to Go

Photo by GB The Green Brand via Pexels.

Drive out to Raymond, a small community just northwest of Lincoln, and you'll find MahāMotā Cultivation sitting on a crop that, as of September 2026, was roughly four to six weeks from its first harvest. That's a cultivator doing exactly what the state licensed it to do -- growing cannabis under a regulatory framework that voters approved nearly two years ago. The problem is what happens after the plants come down.

There is no licensed testing laboratory anywhere in Nebraska. None. That means there's no legal mechanism to verify potency, screen for pesticides or microbial contamination, or clear harvested cannabis for anything beyond sitting in storage. Even if a lab existed, there's no licensed manufacturer to turn flower into an approved tincture or capsule, and no licensed transporter to move product between facilities even if one did exist. The supply chain Nebraska built on paper simply doesn't function yet in practice.

Garrett Elting, one of the growers navigating this, has been blunt about what that delay actually costs. Cannabis biomass doesn't hold its value sitting in a warehouse -- terpenes degrade, cannabinoid potency drops, and the clock doesn't stop just because the state's paperwork isn't finished. Every week without a buyer is a week of quality loss on a product that's already expensive to grow under strict compliance conditions.

The commission's own position hasn't helped speed things along. Officials have said publicly they won't move forward on manufacturer or dispensary licensing until the fees tied to those license categories are formally authorized. Ten manufacturer applications came in by the September 14, 2026 deadline -- a real signal of market interest -- but as of this writing, not one has been approved. The applicants are waiting on the same regulatory bottleneck as the growers.

The Fee Fight Pushing Licensing Into 2027

Photo by Mariakray via Pixabay.

The bottleneck has a name, and it's fees. On October 15, 2026, the commission held a public hearing on proposed fee amendments at 301 Centennial Mall South in Lincoln -- the kind of unglamorous administrative meeting that rarely makes headlines but is currently the single biggest obstacle standing between Nebraska patients and an actual dispensary. Public comments from that hearing now have to be reviewed before the commission can finalize its regulations, and even once that's done, the approved rules still need sign-off from both the governor and the attorney general. The commission itself has said that process will likely stretch into 2027.

The pressure from industry is mounting. On the same day as the hearing, all four of Nebraska's licensed cultivators sent a joint letter to the commission urging it to resolve lab licensing and fee assessment, saying they need what they called a viable path to revenue before the capital they've already sunk into compliant grow operations turns into a total loss. That letter also pushed the Legislature to pass legal protections for physicians who recommend medical cannabis to patients -- protections that would shield doctors from professional liability concerns tied to recommending a federally illegal substance. Bills aimed at providing that cover died in both the 2025 and 2026 legislative sessions.

Layered on top of the fee delay is a leadership vacuum. Dr. Monica Oldenburg, who chaired the commission, resigned in February 2026, and Gov. Jim Pillen has yet to name a replacement -- meaning the commission has been working through its most consequential rulemaking stretch without a permanent chair. The commission did hire its first executive director, Brett Long, but not until September 2026, nearly a year and a half after the agency began operating. For a program already running behind, losing both a chair and going without an executive director for most of 2026 hasn't exactly accelerated things.

The Lawsuits That Nearly Killed the Program

Photo by sergeitokmakov via Pixabay.

For a stretch, the fee delays weren't even the program's biggest problem -- it was the possibility that courts would kill the whole thing outright. Former state Sen. John Kuehn filed two separate lawsuits against the medical cannabis program, both backed by Attorney General Mike Hilgers and Secretary of State Bob Evnen, two of the state's most powerful elected officials lining up against a voter-approved initiative.

The first suit alleged signature fraud in the petition drive that got the measures onto the 2024 ballot in the first place -- essentially arguing the whole process should be invalidated at its origin. The Nebraska Supreme Court rejected it unanimously, 7-0, in an opinion authored by Chief Justice Jeffrey Funke and issued September 4, 2026. A week later, on September 11, the same court dismissed Kuehn's second suit, which had argued the state program was preempted by federal law -- a familiar argument in cannabis litigation nationally, and one that has rarely succeeded against state medical programs.

There was a period when the threat looked even broader. The attorney general's office had signaled it might sue once actual licenses were issued, suggesting the state itself could challenge its own commission's work. That challenge never materialized -- cultivators got licensed in October 2025, and no suit followed. As of October 2026, no other legal challenge to the program has been filed in Nebraska.

Hilgers' office hasn't dropped cannabis litigation altogether, though. It's joined a federal lawsuit challenging the Department of Justice's move of marijuana to Schedule III under the Controlled Substances Act, a reclassification that took effect in April 2026 under Attorney General Todd Blanche. So while the direct assault on Nebraska's program has been cleared off the board by its own Supreme Court, the state's top lawyer is still fighting cannabis policy on a different front entirely.

Politics on the Ballot Again

Photo by Michael Carruth via Unsplash.

None of this is happening in a political vacuum. Both Gov. Jim Pillen and Attorney General Mike Hilgers are up for reelection next month, which puts a stalled, voters-approved program right in the middle of campaign season -- a program neither man championed and one Hilgers actively tried to dismantle in court before the Supreme Court shut that effort down.

Pillen's inaction has a direct, measurable cost here: the Medical Cannabis Commission has been without a permanent chair since Dr. Monica Oldenburg's resignation in February 2026, right as the agency entered its most consequential fee-rulemaking period. A commission steering fee policy, lab licensing, and manufacturer approvals without a chair isn't a technicality -- it's a governance gap during the exact stretch when governance matters most.

The people actually affected by all this aren't abstractions. They're patients who voted by a 71% margin to get legal access to a treatment option, and who nearly two years later still can't buy a single legal cannabis product in their own state. Whatever the administrative justifications -- fee schedules, rulemaking procedure, gubernatorial sign-off chains -- the practical result is the same for someone managing chronic pain or a seizure disorder: the program they voted for doesn't exist yet in any usable form.

And the timeline keeps sliding. With the commission itself projecting that fee rules and the resulting licensing won't wrap up until sometime in 2027, Nebraska's medical cannabis program is on track to take more than three years from ballot approval to actual patient access -- assuming nothing else slips. For a measure that won with landslide support, that's an unusually long runway.

There's a lesson in Nebraska's rollout that other states have learned the hard way too: winning the ballot measure is the easy part. Building a licensing regime, a fee schedule, a testing infrastructure, and an approval chain running through a commission, a governor, and an attorney general's office -- from literally nothing -- is where programs stall for months and then years. Nebraska had to construct all of it from scratch after June 2025, and the gap between a 67% vote and a functioning commission has turned out to be a lot wider than anyone campaigning for the measures probably advertised.

What's notable now is that the obstacles left standing are entirely administrative and political, not legal. The Nebraska Supreme Court closed the door on Kuehn's lawsuits in two unanimous rulings last September, and no other litigant has stepped up to challenge the program since. That's actually the harder problem for advocates, in a way -- a lawsuit has a resolution date and a clear outcome. A fee schedule stuck in rulemaking, a commission chair seat sitting empty for the better part of a year, and physician-protection bills dying quietly in back-to-back legislative sessions don't resolve on anyone's timeline. There's no single ruling that fixes any of that. It just requires people in office to do the unglamorous work of finishing it.

The next real checkpoints are the 2027 legislative session and whatever comes out of the fee rulemaking the commission says it's targeting for sometime in 2027. That's where it'll become clear whether Nebraska's medical cannabis program actually opens its doors to the patients who voted for it, or whether it keeps sliding the way it has since October 2024.